Long-term use of rosuvastatin: a critical risk benefit appraisal and comparison with other antihyperlipidemics

Rosuvastatin represents the latest inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase introduced in clinical practice for the treatment of hypercholesterolemia. In comparative trials, across dose ranges this statin reduced low-density lipoprotein (LDL) cholesterol and total chole...

Descripción completa

Detalles Bibliográficos
Autor principal: Calza, Leonardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108688/
https://www.ncbi.nlm.nih.gov/pubmed/21701608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108688/
https://www.ncbi.nlm.nih.gov/pubmed/21701608

Ejemplares similares